Results from the AURORAS-1 Phase I clinical trial of an anticancer drug called ERAS-0015 have shown that it is safe and has caused tumors to shrink in hard-to-treat diseases such as lung and pancreatic cancer.
'Pan-RAS molecular glue' drug ERAS-0015 shows safety and efficacy in Phase I trials for lung and pancreatic cancers
A new anticancer drug called ERAS-0015 has shown promising results in Phase I clinical trials for treating lung and pancreatic cancers. The drug uses 'pan-RAS molecular glue' technology and demonstrated safety and tumor shrinkage in patients with difficult-to-treat cancers. This development has no direct relevance to Iran's political, economic, military, or human rights situation.
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%